A Phase 3 interventional study of Idelalisib and Ofatumumab in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 80 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 5th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 9th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 6th largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2012, is one of 9 in phase 3, and was the 16th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
Key Inclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone.
Drug: Idelalisib · Drug: Ofatumumab
Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone.
Drug: Ofatumumab
150 mg tablets administered orally twice daily
Also known as: Zydelig®, GS-1101, CAL-101
Administered intravenously
Also known as: Arzerra®
Progression-Free Survival
Progression-free survival (PFS) was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL. PFS was analyzed using Kaplan-Meier (KM) estimates.
Time frame: Randomization to End of Study (up to 60 months)
Overall Response Rate
Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. * Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. * Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. Overall response rate was analyzed using KM estimates.
Time frame: Randomization to End of Study (up to 60 months)
Lymph Node Response Rate
Lymph node response rate was defined as the proportion of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.
Time frame: Randomization to End of Study (up to 60 months)
Overall Survival
Overall survival was defined as the interval from randomization to death from any cause. Overall survival was analyzed using KM estimates.
Time frame: Randomization to Last Long-Term Follow-Up Visit (up to maximum of 5 years)
Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation
Progression-free survival in subgroup of participants with chromosome 17p deletion and/or TP53 mutation was analyzed using KM estimates.
Time frame: Randomization to End of Study (up to 60 months)
Complete Response Rate
Complete response rate was defined as the percentage of participants who achieve a complete response and maintain their response for at least 8 weeks (with a 1-week window).
Time frame: Randomization to End of Study (up to 60 months)
Participants were enrolled at study sites in North America, Europe, and Australia. The first participant was screened on 04 December 2012. The last study visit occurred on 15 August 2018.
| Milestone | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Started | 174 | 87 |
| Randomized and treated | 173 | 86 |
| Completed | 100 | 50 |
| Not completed | 74 | 37 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Unknown reasons | 2 | 1 |
| Withdrew: Physician decision | 34 | 16 |
| Withdrew: Withdrawal by subject | 19 | 16 |
| Withdrew: Study terminated by sponsor | 16 | 1 |
| Milestone | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Started | 138 | 69 |
| Completed | 133 | 65 |
| Not completed | 5 | 4 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Withdrawal by subject | 2 | 1 |
Progression-free survival (PFS) was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL. PFS was analyzed using Kaplan-Meier (KM) estimates.
| months | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Progression-Free Survival | 16.6 (13.7 to 19.6) | 8.0 (5.7 to 8.4) |
Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. * Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. * Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. Overall response rate was analyzed using KM estimates.
| percentage of participants | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Overall Response Rate | 75.3 (68.2 to 81.5) | 17.2 (10.0 to 26.8) |
Lymph node response rate was defined as the proportion of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.
| percentage of participants | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Lymph Node Response Rate | 92.7 (87.6 to 96.2) | 4.9 (1.4 to 12.2) |
Overall survival was defined as the interval from randomization to death from any cause. Overall survival was analyzed using KM estimates.
| months | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Overall Survival | 45.2 (34.1 to NA) | 39 (23.0 to NA) |
Progression-free survival in subgroup of participants with chromosome 17p deletion and/or TP53 mutation was analyzed using KM estimates.
| months | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation | 16.2 (11.1 to 19.1) | 5.8 (4.5 to 8.4) |
Complete response rate was defined as the percentage of participants who achieve a complete response and maintain their response for at least 8 weeks (with a 1-week window).
| percentage of participants | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| Complete Response Rate | 1.1 | 0 |
Collected over Adverse Events: Start of Treatment to End of Treatment (up to 60 months) plus 30 days; All-Cause Mortality: Baseline to Last Long-Term Follow-Up Visit (up to maximum of 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib+Ofatumumab | 87/174 (50%) | 136/173 (78.6%) | 167/173 (96.5%) |
| Ofatumumab | 40/87 (46%) | 36/86 (41.9%) | 79/86 (91.9%) |
| Event | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| PneumoniaInfections and infestations | 27/173 | 9/86 |
| DiarrhoeaGastrointestinal disorders | 23/173 | 0/86 |
| PyrexiaGeneral disorders | 23/173 | 1/86 |
| Febrile neutropeniaBlood and lymphatic system disorders | 19/173 | 3/86 |
| NeutropeniaBlood and lymphatic system disorders | 13/173 | 2/86 |
| ColitisGastrointestinal disorders | 13/173 | 0/86 |
| SepsisInfections and infestations | 11/173 | 1/86 |
| AnaemiaBlood and lymphatic system disorders | 8/173 | 2/86 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 8/173 | 0/86 |
| Abdominal painGastrointestinal disorders | 7/173 | 1/86 |
| Event | Idelalisib+Ofatumumab | Ofatumumab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 96/173 | 21/86 |
| NauseaGastrointestinal disorders | 62/173 | 23/86 |
| FatigueGeneral disorders | 60/173 | 24/86 |
| CoughRespiratory, thoracic and mediastinal disorders | 60/173 | 18/86 |
| NeutropeniaBlood and lymphatic system disorders | 57/173 | 14/86 |
| PyrexiaGeneral disorders | 55/173 | 19/86 |
| Upper respiratory tract infectionInfections and infestations | 47/173 | 9/86 |
| Infusion related reactionInjury, poisoning and procedural complications | 30/173 | 23/86 |
| ConstipationGastrointestinal disorders | 39/173 | 13/86 |
| AnaemiaBlood and lymphatic system disorders | 38/173 | 7/86 |
Intent-to-Treat (ITT) Analysis Set included participants who were randomized in the study regardless of whether they received any study drug(s), or received a different regimen from that to which they were randomized. Treatment assignment was designated according to randomization.
| Age, Continuous(years) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| Mean | 67 ± 9.0 | 67 ± 9.7 | 67 ± 9.2 |
| Sex: Female, Male(Participants) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| Female | 50 | 25 | 75 |
| Male | 124 | 62 | 186 |
| Ethnicity (NIH/OMB)(Participants) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 3 | 10 |
| Not Hispanic or Latino | 141 | 74 | 215 |
| Unknown or Not Reported | 26 | 10 | 36 |
| Race/Ethnicity, Customized(Participants) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| White | 149 | 71 | 220 |
| Black or African American | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Asian | 2 | 0 | 2 |
| Other | 2 | 3 | 5 |
| Not Permitted | 20 | 9 | 29 |
| Region of Enrollment(Participants) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| Canada | 13 | 9 | 22 |
| Sweden | 4 | 2 | 6 |
| Belgium | 5 | 1 | 6 |
| United States | 64 | 29 | 93 |
| Ireland | 7 | 4 | 11 |
| Denmark | 4 | 0 | 4 |
| Poland | 27 | 9 | 36 |
| United Kingdom | 11 | 6 | 17 |
| Australia | 16 | 13 | 29 |
| France | 15 | 9 | 24 |
| Spain | 8 | 5 | 13 |
| Time Since Diagnosis(months) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| Mean | 101.0 ± 60.21 | 94.3 ± 52.51 | 98.8 ± 57.75 |
| 17p deletion and/or TP53 mutation(Participants) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| Either | 70 | 33 | 103 |
| Neither | 104 | 54 | 158 |
| Immunoglobulin heavy chain variable region (IGHV) mutation status(Participants) | Idelalisib+Ofatumumab | Ofatumumab | Total |
|---|---|---|---|
| Mutated | 37 | 19 | 56 |
| Unmutated | 137 | 68 | 205 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Dec 2012 to primary completion in Aug 2018, 68 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →